Quantbot Technologies LP Purchases Shares of 1,297 Medpace Holdings, Inc. $MEDP

Quantbot Technologies LP purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,297 shares of the company’s stock, valued at approximately $687,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. NewEdge Advisors LLC lifted its position in shares of Medpace by 22.1% in the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after buying an additional 190 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Medpace by 3.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after buying an additional 3,010 shares in the last quarter. Geneos Wealth Management Inc. increased its stake in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in Medpace in the 2nd quarter worth approximately $296,000. Finally, M&T Bank Corp raised its holdings in shares of Medpace by 3.4% during the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after acquiring an additional 31 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of Medpace stock opened at $611.57 on Friday. The stock has a market cap of $17.07 billion, a price-to-earnings ratio of 35.85, a price-to-earnings-growth ratio of 2.76 and a beta of 1.15. The stock has a 50 day moving average price of $562.52 and a 200-day moving average price of $493.80. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.Medpace’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on MEDP shares. Barclays set a $600.00 target price on Medpace in a research report on Thursday, July 23rd. BMO Capital Markets upped their price target on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday, July 24th. Mizuho increased their price objective on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and lifted their price objective for the stock from $490.00 to $515.00 in a research note on Tuesday, July 7th. Finally, Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Three research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $584.18.

Insider Activity

In related news, CEO August J. Troendle sold 27,174 shares of Medpace stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $618.79, for a total transaction of $16,814,999.46. Following the completion of the transaction, the chief executive officer directly owned 561,195 shares of the company’s stock, valued at approximately $347,261,854.05. The trade was a 4.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Susan E. Burwig sold 7,500 shares of Medpace stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the transaction, the vice president directly owned 62,984 shares of the company’s stock, valued at approximately $37,790,400. This represents a 10.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 129,963 shares of company stock worth $79,364,624. 20.50% of the stock is currently owned by insiders.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.